THIS IS A SOURCES SOUGHT NOTICE ONLY. THIS IS NOT A REQUEST FOR PROPOSAL. The Department of Veterans Affairs, VHA, Network Contracting Office (NCO) 19 Rocky Mountain Acquisition Center is seeking potential sources that are capable of providing, testing for the detection of unique genetic alterations (to include mutations, insertions, deletions, fusion and gene expression) to help determine if a thyroid nodule is benign or malignant in fine needle aspirates (FNAs) on behalf of the following VISN 19 locations: Rocky Mountain Regional VA Medical Center (RMRVAMC), 1700 North Wheeling Street, Aurora, CO, 80045 NCO 19 is performing market research to determine if there is a sufficient number of qualified (1) Service Disabled Veteran Owned Small Business (SDVOSB); (2) Veteran Owned Small Business (VOSB); (3) Small or emerging small business firms; or (4) Large businesses who can fulfill the requirement. This Sources Sought notice is issued for the purpose of market research in accordance with Federal Acquisition Regulation (FAR) Part 10. All SDVOSB, VOSB, small and large businesses capable of fulfilling the requirement are invited to respond. NAICS code to be used for this acquisition is 621511. All interested firms who can meet the requirements stated in Summary of Requirements below should respond, in writing, with the following information: Interest and Capabilities Address and DUNS Business category (SDVOSB, VOSB, Small Business, or Large Business) State if interested firm has a NAC or GSA contract by replying with their applicable contract number Any information submitted by respondents to this sources sought synopsis is voluntary. This sources sought notice is not to be construed as a commitment by the Government, nor will the Government reimburse any costs associated with the submission of information in response to this notice. Respondents will not individually be notified of the results of any Government assessments. Responses and questions may be submitted electronically to: [email protected] in a Microsoft word compatible format no later than Wednesday, March 31st, 2021, at 4:30pm Mountain Time. PHONE CALLS NOT ACCEPTED. SUMMARY OF REQUIREMENTS: The RMRVAMC requires access to a molecular assay which analyzes thyroid fine needle aspiration specimens from patients who have had a previous diagnosis of atypical cells of undetermined significance . The purpose of the test is to detect mutations which would predispose a patient to increased risk of thyroid carcinoma. This test would decrease the need for repeat biopsies from the patient, which, in turn, reduces the risk of procedure-related complications and optimize patient follow-up. An ideal molecular test to evaluate thyroid nodules with indeterminate cytology should have a negative predictive value that is comparable to that of benign thyroid cytology (< 3%). Thus, a negative test could allow for thyroid surgery to be safely avoided. Contractor shall provide testing for the detection of unique genetic alterations (to include mutations, insertions, deletions, fusion and gene expression) to help determine if a thyroid nodule is benign or malignant in fine needle aspirates (FNAs) that are read indeterminate (Bethesda III and IV) by a Rocky Mountain Regional VA Medical Center provider. Samples will be sent from the Rocky Mountain Regional VA Medical Center (RMRVAMC), located at 1700 North Wheeling Street, Aurora, CO, 80045. Targeted mutation detection for thyroid samples may include BRAF testing Fine Needle Aspiration (FNA) Cytology slide smears FNA Cell Block Resected Tissue (tumors) Any other acceptable sample types (End of Document)

Bid Protests Not Available